Literature DB >> 17967915

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Glenn A Pankuch1, Gengrong Lin, Harald Seifert, Peter C Appelbaum.   

Abstract

Time-kill synergy studies showed that at 24 h, subinhibitory meropenem and ciprofloxacin concentrations of 0.06 to 128 and 0.03 to 32 microg/ml, respectively, showed synergy against 34/51 Pseudomonas aeruginosa strains; subinhibitory concentrations of meropenem (0.06 to 8 microg/ml) and colistin (0.12 to 1 microg/ml) showed synergy against 13 isolates. Subinhibitory meropenem and ciprofloxacin concentrations of 0.25 to 2 and 0.12 to 16 microg/ml, respectively, showed synergy against 18/52 Acinetobacter baumannii strains at 24 h. Subinhibitory meropenem and colistin concentrations of 0.03 to 64 and 0.06 to 8 microg/ml, respectively, showed synergy against 49 strains at 24 h.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967915      PMCID: PMC2223893          DOI: 10.1128/AAC.00689-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Epidemiology and control of antibiotic resistance in the intensive care unit.

Authors:  Jean Carlet; Adel Ben Ali; Annie Chalfine
Journal:  Curr Opin Infect Dis       Date:  2004-08       Impact factor: 4.915

2.  Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.

Authors:  Serhat Unal; Jose Angel Garcia-Rodriguez
Journal:  Diagn Microbiol Infect Dis       Date:  2005-12       Impact factor: 2.803

3.  Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.

Authors:  Joshua S Hawley; Clinton K Murray; Matthew E Griffith; M Leticia McElmeel; Letitia C Fulcher; Duane R Hospenthal; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics.

Authors:  J. Moira Greenhalgh; Jeffrey R. Edwards
Journal:  Clin Microbiol Infect       Date:  1997-02       Impact factor: 8.067

Review 6.  Treatment options for multidrug-resistant bacteria.

Authors:  Helen Giamarellou
Journal:  Expert Rev Anti Infect Ther       Date:  2006-08       Impact factor: 5.091

7.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

8.  Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp.

Authors:  H J Grundmann; K J Towner; L Dijkshoorn; P Gerner-Smidt; M Maher; H Seifert; M Vaneechoutte
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

9.  Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more
  34 in total

1.  Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae.

Authors:  Spyros Pournaras; Ioulia Kristo; Georgia Vrioni; Alexandros Ikonomidis; Aggeliki Poulou; Dimitra Petropoulou; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.

Authors:  Kim Credito; Gengrong Lin; Laura Koeth; Michael A Sturgess; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 4.  Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Authors:  Phillip J Bergen; Zackery P Bulman; Sarith Saju; Juergen B Bulitta; Cornelia Landersdorfer; Alan Forrest; Jian Li; Roger L Nation; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2015-01       Impact factor: 4.705

5.  Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.

Authors:  Phillip J Bergen; Alan Forrest; Jürgen B Bulitta; Brian T Tsuji; Hanna E Sidjabat; David L Paterson; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

6.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

7.  Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; Jovan Jacob; Hanna E Sidjabat; David L Paterson; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

8.  Pharmacological Inhibition of the Pseudomonas aeruginosa MvfR Quorum-Sensing System Interferes with Biofilm Formation and Potentiates Antibiotic-Mediated Biofilm Disruption.

Authors:  Damien Maura; Laurence G Rahme
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

9.  Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers.

Authors:  J N Suresh Kumar; Prameela Devi; Lakshmi Narasu; Ramesh Mullangi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

10.  New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors.

Authors:  Laurent Mamelli; Sylvain Petit; Jacqueline Chevalier; Carmela Giglione; Aurélie Lieutaud; Thierry Meinnel; Isabelle Artaud; Jean-Marie Pagès
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.